既治療のプログラム細胞死リガンド1（PD-L1）陽性非小細胞肺がん（NSCLC）の成人患者を対象に、PF-08046054/SGN-PDL1Vと呼ばれる試験薬とドセタキセルを比較する試験について学ぶ研究

基本情報

NCT ID

NCT07144280

ステータス

募集中

試験のフェーズ

第3相

試験タイプ

介入

目標被験者数

680

治験依頼者名

Pfizer

概要

The purpose of this study is to understand if PF-08046054 alone works well compared to standard-of-care docetaxel alone in participants with non-small cell lung cancer (NSCLC) with PD-L1 expression greater than or equal to 1% and had cancer progression during or after treatment with PD-L1 or PD-1 inhibitors, platinum-based chemotherapy, and targeted treatment regimen(s) for participants with known actionable genomic alterations (AGAs). Participants in this study must have cancer that has spread through their body or can't be removed with surgery or treated with definitive radiation. Participants will randomly (like a flip of the coin) be assigned to either the PF-08046054 treatment group or the docetaxel treatment group. Participants in the PF-08046054 treatment group will receive an IV infusion (injected directly into the veins) twice during each 21-day cycle. Participants in the docetaxel treatment group will receive an IV infusion once during each 21-day cycle. Study participation may be up to 5 years if the participant's NSCLC is responding to treatment. The study team will see how each participant is doing with the study treatment during regular visits at the clinic.

対象疾患

介入

依頼者（Sponsor）

実施施設 (14)